{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:47:43Z","timestamp":1791658063447,"version":"4.3.4"},"reference-count":89,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01 NS111990"],"award-info":[{"award-number":["R01 NS111990"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015834","name":"Ono Pharma Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ymthe.2024.10.024","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:05:48Z","timestamp":1730257548000},"page":"4401-4417","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system"],"prefix":"10.1016","volume":"32","author":[{"given":"Michael P.","family":"Moazami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia M.","family":"Rembetsy-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Sarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly R.","family":"McEachern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atish","family":"Wagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranathi Meda","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miklos","family":"Marosfoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Gray-Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5706-1734","authenticated-orcid":false,"given":"Jonathan K.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.10.024_bib1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense Drugs Make Sense for Neurological Diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","article-title":"Antisense oligonucleotides: the next frontier for treatment of neurological disorders","volume":"14","author":"Rinaldi","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag0481","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9","author":"DeVos","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41591-021-01557-6","article-title":"Suppression of mutant C9orf72 expression by a potent mixed backbone antisense oligonucleotide","volume":"28","author":"Tran","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib5","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2017.08.002","article-title":"LRRK2 Antisense Oligonucleotides Ameliorate \u03b1-Synuclein Inclusion Formation in a Parkinson's Disease Mouse Model","volume":"8","author":"Zhao","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.024_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.135633","article-title":"\u03b1-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson's disease","volume":"6","author":"Cole","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.10.024_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.tips.2023.08.008","article-title":"ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis","volume":"44","author":"Jin","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.024_bib9","article-title":"Quantifying and Mitigating Motor Phenotypes Induced by Antisense Oligonucleotides in the Central Nervous System","author":"Moazami","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.ymthe.2024.10.024_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.omtn.2022.12.010","article-title":"Change of intracellular calcium level causes acute neurotoxicity by antisense oligonucleotides via CSF route","volume":"31","author":"Jia","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.024_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/nat.2021.0071","article-title":"Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features","volume":"32","author":"Hagedorn","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib12","article-title":"Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+and Mg2+ in the formulation","volume":"2024","author":"Miller","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.024_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1177\/0192623310385255","article-title":"Functional assays for neurotoxicity testing","volume":"39","author":"Moser","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib15","series-title":"Test No. 424: Neurotoxicity Study in Rodents","year":"1997"},{"key":"10.1016\/j.ymthe.2024.10.024_bib16","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","article-title":"Targeting Huntingtin Expression in Patients with Huntington\u2019s Disease","volume":"380","author":"Tabrizi","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Aartsma-Rus","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nn.4508","article-title":"Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy","volume":"20","author":"Corey","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymthe.2024.10.024_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1101\/gad.1941310","article-title":"Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model","volume":"24","author":"Hua","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.ymthe.2024.10.024_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001777","article-title":"Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy","volume":"3","author":"Passini","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1083\/jcb.201207087","article-title":"Antisense-based therapy for the treatment of spinal muscular atrophy","volume":"199","author":"Rigo","year":"2012","journal-title":"J.\u00a0Cel Biol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib22","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1056\/NEJMoa1813279","article-title":"Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease","volume":"381","author":"Kim","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.10.024_bib24","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/gt.2017.34","article-title":"How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy","volume":"24","author":"Singh","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib25","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.4049\/jimmunol.176.6.3804","article-title":"Microglia recognize double-stranded RNA via TLR3","volume":"176","author":"Town","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cell.2018.03.064","article-title":"Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response","volume":"173","author":"Jiang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2024.10.024_bib27","doi-asserted-by":"crossref","first-page":"873","DOI":"10.4049\/jimmunol.1402573","article-title":"Cutting edge: AIM2 and endosomal TLRs differentially regulate arthritis and autoantibody production in DNase II-deficient mice","volume":"194","author":"Baum","year":"2015","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib28","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature06726","article-title":"UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes","volume":"452","author":"Kim","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.024_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/nat.2017.0705","article-title":"Intracerebroventricular Administration of a 2'-O-Methyl Phosphorothioate Antisense Oligonucleotide Results in Activation of the Innate Immune System in Mouse Brain","volume":"28","author":"Toonen","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib30","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.2984773","article-title":"Bond order and charge localization in nucleoside phosphorothioates","volume":"228","author":"Frey","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.10.024_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(00)80510-3","article-title":"Neuronal calcium signaling","volume":"21","author":"Berridge","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2024.10.024_bib32","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1007\/s00018-013-1550-7","article-title":"Neuronal calcium signaling: function and dysfunction","volume":"71","author":"Brini","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymthe.2024.10.024_bib33","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/j.1471-4159.1986.tb13082.x","article-title":"Homeostasis of brain and cerebrospinal fluid calcium concentrations during chronic hypo- and hypercalcemia","volume":"47","author":"Murphy","year":"1986","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ymthe.2024.10.024_bib35","series-title":"QALSODY (Tofersen) [package Insert]","year":"2023"},{"key":"10.1016\/j.ymthe.2024.10.024_bib36","series-title":"SPINRAZA (NUSINERSEN) [package Insert]","year":"2016"},{"key":"10.1016\/j.ymthe.2024.10.024_bib37","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3171\/jns.1949.6.2.0140","article-title":"Physiological salt solutions for brain surgery; studies of local pH and pial vessel reactions to buffered and unbuffered isotonic solutions","volume":"6","author":"Elliott","year":"1949","journal-title":"J.\u00a0Neurosurg."},{"key":"10.1016\/j.ymthe.2024.10.024_bib38","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1089\/nat.2013.0443","article-title":"Characterization of target mRNA reduction through in\u00a0situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals","volume":"23","author":"Hung","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib39","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2024.10.024_bib40","article-title":"Artificial cerebrospinal fluid (ACSF)","author":"Laboratory","year":"2011","journal-title":"Cold Spring Harbor Protoc."},{"key":"10.1016\/j.ymthe.2024.10.024_bib41","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0022-510X(79)90194-1","article-title":"Magnesium and inorganic phosphate content in CSF related to blood-brain barrier function in neurological disease","volume":"40","author":"Heipertz","year":"1979","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.ymthe.2024.10.024_bib42","first-page":"16","article-title":"Intrathecal delivery of protein therapeutics to treat genetic diseases involving the CNS","volume":"1","author":"Shahrokh","year":"2010","journal-title":"ONDRUGDELIVERY"},{"key":"10.1016\/j.ymthe.2024.10.024_bib43","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/acs.biochem.8b00827","article-title":"Next-Generation Peptide Nucleic Acid Chimeras Exhibit High Affinity and Potent Gene Silencing","volume":"58","author":"Debacker","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2024.10.024_bib44","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1093\/nar\/gkz247","article-title":"Site-specific replacement of phosphorothioate with alkyl phosphonate linkages enhances the therapeutic profile of gapmer ASOs by modulating interactions with cellular proteins","volume":"47","author":"Migawa","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib45","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1093\/nar\/gkac037","article-title":"Impact of guanidine-containing backbone linkages on stereopure antisense oligonucleotides in the CNS","volume":"50","author":"Kandasamy","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/nar\/gkaa1235","article-title":"The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration","volume":"49","author":"Jafar-Nejad","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib47","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI25424","article-title":"Antisense oligonucleotide therapy for neurodegenerative disease","volume":"116","author":"Smith","year":"2006","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.10.024_bib48","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"\u00d8stergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib49","doi-asserted-by":"crossref","first-page":"12887","DOI":"10.1523\/JNEUROSCI.2107-13.2013","article-title":"Antisense reduction of tau in adult mice protects against seizures","volume":"33","author":"DeVos","year":"2013","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.ymthe.2024.10.024_bib50","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/nature13975","article-title":"Towards a therapy for Angelman syndrome by targeting a long non-coding RNA","volume":"518","author":"Meng","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.024_bib51","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.neuron.2016.04.006","article-title":"Gain of Toxicity from ALS\/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs","volume":"90","author":"Jiang","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.ymthe.2024.10.024_bib52","doi-asserted-by":"crossref","first-page":"e123193","DOI":"10.1172\/jci.insight.123193","article-title":"Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles","volume":"3","author":"Friedrich","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2024.10.024_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbi.2017.11.007","article-title":"Intrathecal administration of antisense oligonucleotide against p38\u03b1 but not p38\u03b2 MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice","volume":"72","author":"Luo","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ymthe.2024.10.024_bib54","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nature16159","article-title":"Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides","volume":"528","author":"Sztainberg","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.024_bib55","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.omtn.2017.04.005","article-title":"Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models","volume":"7","author":"Moore","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.024_bib56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/j.pain.0000000000001074","article-title":"Antisense oligonucleotides selectively suppress target RNA in nociceptive neurons of the pain system and can ameliorate mechanical pain","volume":"159","author":"Mohan","year":"2018","journal-title":"Pain"},{"key":"10.1016\/j.ymthe.2024.10.024_bib57","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI99081","article-title":"Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models","volume":"128","author":"McCampbell","year":"2018","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2024.10.024_bib58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbd.2018.03.002","article-title":"Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis","volume":"114","author":"Ling","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ymthe.2024.10.024_bib59","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nature22038","article-title":"Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice","volume":"544","author":"Becker","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.024_bib60","series-title":"Presented at the Cold Spring Harbor Laboratory meeting on Nucleic Acid Therapies","author":"Hagedorn","year":"2023"},{"key":"10.1016\/j.ymthe.2024.10.024_bib61","doi-asserted-by":"crossref","first-page":"26801","DOI":"10.1016\/S0021-9258(18)47090-1","article-title":"Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding","volume":"269","author":"Brown","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.10.024_bib62","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev.pharmtox.41.1.403","article-title":"Antisense oligonucleotides: promise and reality","volume":"41","author":"Lebedeva","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib63","series-title":"Antisense Drug Technology: Principles, Strategies, and Applications","article-title":"Basic Principles of Pharmacokinetics of Antisense Oligonucleotide Drugs","author":"Levin","year":"2008"},{"key":"10.1016\/j.ymthe.2024.10.024_bib64","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib65","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/0014-5793(95)00517-D","article-title":"Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23\/nucleolin","volume":"366","author":"Weidner","year":"1995","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ymthe.2024.10.024_bib66","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1158\/1078-0432.CCR-08-2610","article-title":"G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in\u00a0vitro endothelial cell growth and tubular morphogenesis","volume":"15","author":"Stein","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib67","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/nar\/gky145","article-title":"Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides","volume":"46","author":"Wang","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib68","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/nar\/gkw112","article-title":"Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver","volume":"44","author":"Miller","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib69","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1021\/jacs.9b13524","article-title":"Origins of the Increased Affinity of Phosphorothioate-Modified Therapeutic Nucleic Acids for Proteins","volume":"142","author":"Hyjek-Skladanowska","year":"2020","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ymthe.2024.10.024_bib70","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1073\/pnas.94.6.2620","article-title":"Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in\u00a0vitro and in\u00a0vivo studies","volume":"94","author":"Agrawal","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.10.024_bib71","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0378-4274(95)03573-7","article-title":"Novel enzymatic and immunological responses to oligonucleotides","volume":"82\u201383","author":"Agrawal","year":"1995","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.ymthe.2024.10.024_bib72","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0022-3565(25)20701-7","article-title":"Pharmacokinetics and tissue disposition of a chimeric oligodeoxynucleoside phosphorothioate in rats after intravenous administration","volume":"278","author":"Zhang","year":"1996","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0006-2952(95)02177-9","article-title":"Effect of different chemically modified oligodeoxynucleotides on immune stimulation","volume":"51","author":"Zhao","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib74","series-title":"Antisense Drug Technology: Principles, Strategies and Application","article-title":"Toxicologic Properties of 2'-O-Methoxyethyl Chimeric Antisense Inhibitors in Animals and Man","author":"Henry","year":"2007"},{"key":"10.1016\/j.ymthe.2024.10.024_bib75","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/nar\/gky1260","article-title":"Characterization of the interactions of chemically-modified therapeutic nucleic acids with plasma proteins using a fluorescence polarization assay","volume":"47","author":"Gaus","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib76","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0041-008X(87)90180-3","article-title":"Comparative acute toxicity of chlorocitrate and fluorocitrate in dogs","volume":"89","author":"Bosakowski","year":"1987","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib77","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/bi00866a011","article-title":"Hydrogen ion buffers for biological research","volume":"5","author":"Good","year":"1966","journal-title":"Biochemistry"},{"key":"10.1016\/j.ymthe.2024.10.024_bib78","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/abio.1996.0406","article-title":"Electrochemical evidence of surfactant activity of the hepes pH buffer which may have implications on trace metal availability to cultures in\u00a0vitro","volume":"241","author":"Vasconcelos","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ymthe.2024.10.024_bib79","first-page":"171","article-title":"Detection of Small Quantities of Perchlorates","volume":"85","author":"Kruger","year":"1931","journal-title":"Z.\u00a0Anal. Chem."},{"key":"10.1016\/j.ymthe.2024.10.024_bib80","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/nar\/gkv1210","article-title":"Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts","volume":"44","author":"Burel","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2024.10.024_bib81","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.omtn.2017.07.003","article-title":"Strategies for In\u00a0Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs","volume":"8","author":"Kamola","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2024.10.024_bib82","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib83","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1096\/fj.04-1711fje","article-title":"Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1","volume":"19","author":"Oshio","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.ymthe.2024.10.024_bib84","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00401-018-1916-x","article-title":"Rapid lymphatic efflux limits cerebrospinal fluid flow to the brain","volume":"137","author":"Ma","year":"2019","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ymthe.2024.10.024_bib85","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060908","article-title":"Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models","volume":"12","author":"Saoudi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.10.024_bib86","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1039\/C7CC04092J","article-title":"Synthesis and biological properties of triazole-linked locked nucleic acid","volume":"53","author":"Sharma","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.ymthe.2024.10.024_bib87","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1074-7613(00)80596-8","article-title":"Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function","volume":"9","author":"Adachi","year":"1998","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2024.10.024_bib88","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.10.024_bib89","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.ymthe.2019.11.012","article-title":"A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna","volume":"28","author":"Taghian","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.10.024_bib90","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/nat.2015.0578","article-title":"A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In\u00a0Vivo","volume":"26","author":"Coles","year":"2016","journal-title":"Nucleic Acid Ther."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624006841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:41:43Z","timestamp":1762548103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624006841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1525001624006841"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.024","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.14.431096","asserted-by":"object"}]},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}